Zubair Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zubair Hussain has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Asad Nawaz
2 shared publications- Yong Wu
The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China
2 shared publications Adnan Falak Naz
Department of Dermatology and Venereology, The Third Xiangya Hospital of Central South University, Changsha 410013, China
1 shared publicationAdnan Naz
1 shared publicationAgila Mohammed
1 shared publicationChenxing Zeng
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in SSRN Electronic Journal
Divergent global trajectories of oesophageal squamous-cell carcinoma mortality, 1990 to 2040: a six-region modelling study
Background Oesophageal squamous-cell carcinoma (ESCC) is a leading cause of cancer death in low and middle SDI regions. We characterised the heterogeneity of mortality trajectories across six world regions using contemporary methods. Methods We analysed Global Burden of Disease Study 2021 age-standardised mortality rates (1990-2021) using dynamic-programming changepoint detection, Bayesian state-space forecasting to 2040, Das Gupta demographic decomposition, and stochastic frontier analysis. Results Global ASMR declined from 9.01 to 6.12 per 100,000 (AAPC -1.24% per year, 95% CI -1.49 to -1.01), with a synchronised inflection at 2005. Central Asia showed the steepest decline (AAPC -3.30%), whereas Western Sub-Saharan Africa was the only region with a rising trajectory (AAPC +1.56%). Bayesian projections indicate a further 41% rise in Western Sub-Saharan Africa by 2040. East Asia operated at 40% of the achievable burden minimum. Conclusions ESCC mortality trajectories are diverging globally. Region-specific interventions including tobacco control, hot-beverage cooling, mycotoxin mitigation, and AI-assisted endoscopy are needed to reduce preventable mortality.
- 15 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDivergent global trajectories of oesophageal squamous-cell carcinoma mortality, 1990 to 2040: a six-region modelling study
Background Oesophageal squamous-cell carcinoma (ESCC) is a leading cause of cancer death in low and middle SDI regions. We characterised the heterogeneity of mortality trajectories across six world regions using contemporary methods. Methods We analysed Global Burden of Disease Study 2021 age-standardised mortality rates (1990-2021) using dynamic-programming changepoint detection, Bayesian state-space forecasting to 2040, Das Gupta demographic decomposition, and stochastic frontier analysis. Results Global ASMR declined from 9.01 to 6.12 per 100,000 (AAPC -1.24% per year, 95% CI -1.49 to -1.01), with a synchronised inflection at 2005. Central Asia showed the steepest decline (AAPC -3.30%), whereas Western Sub-Saharan Africa was the only region with a rising trajectory (AAPC +1.56%). Bayesian projections indicate a further 41% rise in Western Sub-Saharan Africa by 2040. East Asia operated at 40% of the achievable burden minimum. Conclusions ESCC mortality trajectories are diverging globally. Region-specific interventions including tobacco control, hot-beverage cooling, mycotoxin mitigation, and AI-assisted endoscopy are needed to reduce preventable mortality.
- Open Access
- 27 March 2026
- Published by Springer Nature
Differential Gene Expression Analysis of TCGA Cancer Transcriptomes with DESeq2 and Pathway Enrichment v1
This protocol provides a validated workflow for differential gene expression analysis of TCGA RNA-seq data. It covers data retrieval via TCGAbiolinks, normalization decisions, differential expression with DESeq2 and apeglm shrinkage, gene ID conversion, and three pathway analysis approaches: ORA, GSEA, and sample-level scoring with GSVA. Each step includes benchmark values validated against TCGA-LUAD (n=540 tumor, 59 normal). The protocol addresses common pitfalls including inappropriate use of TPM for statistical testing and pre-filtering of gene lists before GSEA.
- 27 March 2026
- Published by Springer Nature
Open AccessDifferential Gene Expression Analysis of TCGA Cancer Transcriptomes with DESeq2 and Pathway Enrichment v1
This protocol provides a validated workflow for differential gene expression analysis of TCGA RNA-seq data. It covers data retrieval via TCGAbiolinks, normalization decisions, differential expression with DESeq2 and apeglm shrinkage, gene ID conversion, and three pathway analysis approaches: ORA, GSEA, and sample-level scoring with GSVA. Each step includes benchmark values validated against TCGA-LUAD (n=540 tumor, 59 normal). The protocol addresses common pitfalls including inappropriate use of TPM for statistical testing and pre-filtering of gene lists before GSEA.
- 16 March 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 19, 1
WITHDRAWN: Design and Evaluation of Floating Micro-Carriers for Effective Delivery of a Hydrophobic Drug
The article has been withdrawn at the request of the authors of the journal "Current Drug Delivery", Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
- 16 March 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 19, 1
WITHDRAWN: Design and Evaluation of Floating Micro-Carriers for Effective Delivery of a Hydrophobic Drug
The article has been withdrawn at the request of the authors of the journal "Current Drug Delivery", Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
- Open Access
- 14 December 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (1)
Triple combination of SPR741, clarithromycin, and erythromycin againstAcinetobacter baumanniiand its tolerant phenotype
Extensively drug-resistant (XDR) Acinetobacter baumannii poses a severe threat to public health due to its ability to form biofilms and persister cells, which contributes to critical drug resistance and refractory device-associated infections. A novel strategy to alleviate such an emergency is to identify promising compounds that restore the antimicrobial susceptibility of existing antibiotics against refractory infections. Here, we found a significant synergy among three combinations of SPR741, clarithromycin and erythromycin with a potent antimicrobial activity against XDR A. baumannii (SPR741/CLA/E at 8/10/10 μg ml–1 for XDR AB1069 and at 10/16/10 μg ml–1 for XDR AB1208, respectively). Moreover, the triple combination therapy exhibits a significant antipersister and antibiofilm effect against XDR strains. Mechanistic studies demonstrate that SPR741 may promote intracellular accumulation of macrolides by permeabilizing the outer membrane as well as disrupting membrane potential and further enhance the quorum sensing inhibition activity of the macrolides against XDR A. baumannii and its biofilms. In addition, the triple combination of SPR741 with clarithromycin and erythromycin was not easy to induce resistance in A. baumannii and had effective antimicrobial activity with low toxicity in vivo. Collectively, these results reveal the potential of SPR741 in combination with clarithromycin and erythromycin as a clinical therapy for refractory infections caused by XDR A. baumannii.
- 14 December 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (1)
Open AccessTriple combination of SPR741, clarithromycin, and erythromycin againstAcinetobacter baumanniiand its tolerant phenotype
Extensively drug-resistant (XDR) Acinetobacter baumannii poses a severe threat to public health due to its ability to form biofilms and persister cells, which contributes to critical drug resistance and refractory device-associated infections. A novel strategy to alleviate such an emergency is to identify promising compounds that restore the antimicrobial susceptibility of existing antibiotics against refractory infections. Here, we found a significant synergy among three combinations of SPR741, clarithromycin and erythromycin with a potent antimicrobial activity against XDR A. baumannii (SPR741/CLA/E at 8/10/10 μg ml–1 for XDR AB1069 and at 10/16/10 μg ml–1 for XDR AB1208, respectively). Moreover, the triple combination therapy exhibits a significant antipersister and antibiofilm effect against XDR strains. Mechanistic studies demonstrate that SPR741 may promote intracellular accumulation of macrolides by permeabilizing the outer membrane as well as disrupting membrane potential and further enhance the quorum sensing inhibition activity of the macrolides against XDR A. baumannii and its biofilms. In addition, the triple combination of SPR741 with clarithromycin and erythromycin was not easy to induce resistance in A. baumannii and had effective antimicrobial activity with low toxicity in vivo. Collectively, these results reveal the potential of SPR741 in combination with clarithromycin and erythromycin as a clinical therapy for refractory infections caused by XDR A. baumannii.
- 24 September 2022
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 80 (1)
Study on antibacterial effect of halicin (SU3327) against Enterococcus faecalis and Enterococcus faecium
Enterococci are important pathogens of nosocomial infections and are increasingly difficult to treat due to their intrinsic and acquired resistance to a range of antibiotics. Therefore, there is an urgent need to develop novel antibacterial agents, while drug repurposing is a promising approach to address this issue. Our study aimed to determine the antimicrobial efficacy of halicin against enterococci and found that the minimum inhibitory concentrations (MIC) of halicin against different strains of Enterococcus faecalis and Enterococcus faecium ranged from 4 to 8 μg/ml. In addition, the synergistic antibacterial effect between halicin and doxycycline (DOX) against Enterococcus was observed through the checkerboard method, and it was observed that halicin and DOX could significantly synergistically inhibit biofilm formation and eradicate preformed biofilms at sub-MICs. Moreover, the electron microscope results revealed that halicin could also disrupt the bacterial cell membrane at high concentrations. Furthermore, it is also confirmed that the combination of halicin and DOX has no significant cytotoxic effect on erythrocytes and other human-derived cells. In addition, the mouse subcutaneous model and H&E staining showed that the combination of halicin and DOX could effectively reduce the bacterial load and inflammatory infiltration without obvious side effects. In nutshell, these results demonstrate the potential of halicin in combination with DOX as a novel therapy against infections by Enterococcus.
- 24 September 2022
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 80 (1)
Study on antibacterial effect of halicin (SU3327) against Enterococcus faecalis and Enterococcus faecium
Enterococci are important pathogens of nosocomial infections and are increasingly difficult to treat due to their intrinsic and acquired resistance to a range of antibiotics. Therefore, there is an urgent need to develop novel antibacterial agents, while drug repurposing is a promising approach to address this issue. Our study aimed to determine the antimicrobial efficacy of halicin against enterococci and found that the minimum inhibitory concentrations (MIC) of halicin against different strains of Enterococcus faecalis and Enterococcus faecium ranged from 4 to 8 μg/ml. In addition, the synergistic antibacterial effect between halicin and doxycycline (DOX) against Enterococcus was observed through the checkerboard method, and it was observed that halicin and DOX could significantly synergistically inhibit biofilm formation and eradicate preformed biofilms at sub-MICs. Moreover, the electron microscope results revealed that halicin could also disrupt the bacterial cell membrane at high concentrations. Furthermore, it is also confirmed that the combination of halicin and DOX has no significant cytotoxic effect on erythrocytes and other human-derived cells. In addition, the mouse subcutaneous model and H&E staining showed that the combination of halicin and DOX could effectively reduce the bacterial load and inflammatory infiltration without obvious side effects. In nutshell, these results demonstrate the potential of halicin in combination with DOX as a novel therapy against infections by Enterococcus.
- 11 May 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 417 (2) , 113192
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax
- 11 May 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 417 (2) , 113192
Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax